Michael Wootton, Co-Founder and Chief Executive Officer
Michael is NFlection’s President and Chief Executive Officer, and also a Co-Founder. He has over fifteen years of strategy and operations consulting experience. He was formerly Partner and Life Sciences Sector Head at Celerant Consulting (acquired by Hitachi Consulting) where he worked with an array of life sciences companies including Bayer, Wyeth, Abbott, Roche, Genzyme, Fresenius, CDC, and others, on large operational strategy programs. Michael is Managing Partner of Vie Capital Partners, an investment and advisory services firm focused on early and growth stage life sciences and healthcare companies. Michael has a bachelor’s degree in mechanical engineering from the University of Waterloo and an MBA from the Harvard Business School.
Karl Beutner, M.D., Ph.D. Chief Medical Officer
Dr. Karl Beutner, M.D., Ph.D., leads NFlection’ drug development efforts. He brings more than 30 years of experience in various leadership and executive roles, most recently as Chief Medical Officer at Anacor Pharmaceuticals (acquired for $5.2B in 2016 by Pfizer). Karl has had a major leadership role in the development of over a dozen approved drugs, has helped create the clinical development plan for well over twenty new molecular entities, and has participated in or managed hundreds of clinical trials through the FDA process. He brings a track-record of unparalleled leadership and success in topical drug development. Karl is a practicing dermatologist and a member of the clinical faculty of the Department of Dermatology at UCSF.
Frederick Reno, Ph.D. Toxicology Advisor
Dr. Reno established a toxicology consulting practice 25 years ago after 20 years with Hazleton Laboratories (now Covance). While with Hazleton, he started as a study director and eventually rose to the position of Vice President over all toxicology operations in Virginia, Maryland and Wisconsin. All of his consulting activities are with various pharmaceutical companies and involve the development of a wide variety of drugs in various stages of development. His client base involves Japanese and European companies as well as those that are based in the United States. In these activities he has frequent contact with the appropriate individuals at the FDA.
Chris O’Mara, Senior Clinical Operations Manager
Chris O’Mara is the Senior Clinical Operations Manager at NFlection. He is a former Senior Clinical Research Coordinator at University of California San Francisco Helen Diller Family Comprehensive Cancer Center, former Clinical Trial Specialist at Ultragenyx Pharmaceutical, Inc, and former Senior Clinical Trial Manager at MyoTherix, Inc. Chris has managed multiple investigator-initiated and sponsored clinical trials across various trial phases in both oncology and rare diseases. He was also a clinical operations subject matter expert for Food and Drug Administration and European Medicines Agency inspections in academia and industry, respectively. Chris holds a Bachelor of Science and Master of Science in biological sciences from Dominican University of California.